Six months into the 117th Congress, the U.S. Senate has recently increased its oversight activities following a slow start. Since April, newly empowered Democratic Members have launched or requested more than 20 inquiries...more
7/6/2021
/ Anti-Competitive ,
Biden Administration ,
Congressional Oversight ,
Coronavirus/COVID-19 ,
Cryptocurrency ,
Cybersecurity ,
Diversity and Inclusion Standards (D&I) ,
Drug Pricing ,
Food and Drug Administration (FDA) ,
Manufacturers ,
Pharmaceutical Industry ,
Popular ,
Relief Measures
The coronavirus (COVID-19) pandemic is significantly altering legislative business in the nation’s capital, but the pandemic has not slowed congressional oversight of the Trump Administration. Congress is actively exercising...more